BPI 221351
Alternative Names: BPI-221351Latest Information Update: 16 Aug 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioma; Solid tumours
Most Recent Events
- 14 Aug 2024 Preclinical trials in Solid tumours in China (PO) prior to August 2024 (Betta Pharmaceuticals pipeline, August 2024)
- 14 Apr 2023 Preclinical trials in Glioma in China (PO)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Glioma presented at the 114th Annual Meeting of the American Association for Cancer Research Session (AACR-2023)